Valuation: Galderma Group AG

Market Cap 50.25B 43.96B 40.55B 37.45B 71.06B 4,793B 72.25B 484B 190B 2,361B 189B 185B 8,117B P/E 2026 *
57.8x
P/E 2027 * 38.6x
Enterprise Value 51.48B 45.03B 41.53B 38.36B 72.79B 4,910B 74.01B 496B 195B 2,419B 193B 189B 8,315B EV / Sales 2026 *
8.16x
EV / Sales 2027 * 6.82x
Free-Float
77.58%
Yield 2026 *
0.26%
Yield 2027 * 0.39%
1 day-0.95%
1 week-4.01%
Current month-6.91%
1 month-1.01%
3 months+7.74%
6 months+7.74%
Current year+5.61%
1 week 169.4
Extreme 169.4
180.2
1 month 166.15
Extreme 166.15
188.25
Current year 136.3
Extreme 136.3
188.25
1 year 122.7
Extreme 122.7
188.25
3 years 60
Extreme 60
188.25
5 years 60
Extreme 60
188.25
10 years 60
Extreme 60
188.25
Date Insider Type Main position Quantity % Market Cap.
29/04Buy 15,000 0.0063%
28/04Sell 25,000 0.0105%
28/04Buy 20,000 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%-4.01%+36.74% - 50.25B
+0.07%+0.87%+2.20%-8.80% 233B
+1.33%-0.65%+128.50% - 9.35B
+1.63%+1.12%+7.36%-55.68% 6.82B
-1.22%+0.33%-8.43%+16.81% 5.07B
-1.72%+2.30%-29.09%-34.97% 4.52B
-1.18%-1.95%-11.19%-11.14% 3.82B
-2.67%-6.23%-32.08%-46.67% 3.34B
+0.62%+1.77%-21.52%-48.66% 2.58B
-0.85%-5.26%0.00% - 1.99B
Average -0.49%-1.78%+7.25%-27.02% 32.02B
Weighted average by Cap. -0.10%-1.17%+10.08%-10.91%

Financials

2026 *2027 *
Net sales 6.3B 5.51B 5.08B 4.69B 8.9B 600B 9.05B 60.68B 23.83B 296B 23.64B 23.12B 1,017B 7.47B 6.53B 6.03B 5.57B 10.56B 712B 10.74B 72B 28.27B 351B 28.04B 27.43B 1,206B
Net income 869M 760M 701M 647M 1.23B 82.87B 1.25B 8.38B 3.29B 40.83B 3.26B 3.19B 140B 1.29B 1.12B 1.04B 958M 1.82B 123B 1.85B 12.39B 4.87B 60.4B 4.83B 4.72B 208B
Net Debt 1.23B 1.07B 989M 913M 1.73B 117B 1.76B 11.81B 4.64B 57.57B 4.6B 4.5B 198B 73.62M 64.4M 59.4M 54.86M 104M 7.02B 106M 710M 279M 3.46B 276M 270M 11.89B
Logo Galderma Group AG
Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.
Employees
7,676
Date Price Change Volume
14/07/26 CHF 171.25 -0.93% 100,801
10/07/26 CHF 172.85 -0.89% 389,388
09/07/26 CHF 174.40 -0.37% 429,693
08/07/26 CHF 175.05 -0.85% 244,611
07/07/26 CHF 176.55 -1.01% 441,494
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
214.24USD
Average target price
232.97USD
Spread / Average Target
+8.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GALD Stock